PBYI — Puma Biotechnology, Inc.
$7.77
$-0.31 (-3.84%)
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Market Cap
$401.70M
Forward P/E
22.2x
52-Week Range
N/A
PBYI Price History
Revenue vs. Net Income
$228M
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$41.7M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
31.4%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
2.5x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
0.0%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+3.2%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
